C4J Stock Overview
C4X Discovery Holdings plc operates as drug discovery company in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
C4X Discovery Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.12 |
| 52 Week High | €0.30 |
| 52 Week Low | €0.059 |
| Beta | 0.23 |
| 1 Month Change | 30.34% |
| 3 Month Change | -12.12% |
| 1 Year Change | -17.14% |
| 3 Year Change | -74.78% |
| 5 Year Change | n/a |
| Change since IPO | -34.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| C4J | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 63.4% | 0.6% | 0.3% |
| 1Y | -17.1% | -3.6% | 8.4% |
Return vs Industry: C4J underperformed the German Life Sciences industry which returned -10.6% over the past year.
Return vs Market: C4J underperformed the German Market which returned 2% over the past year.
Price Volatility
| C4J volatility | |
|---|---|
| C4J Average Weekly Movement | 21.9% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C4J's share price has been volatile over the past 3 months.
Volatility Over Time: C4J's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 49 | Clive Dix | www.c4xdiscovery.com |
C4X Discovery Holdings plc operates as drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules. Its product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer.
C4X Discovery Holdings plc Fundamentals Summary
| C4J fundamental statistics | |
|---|---|
| Market cap | €30.27m |
| Earnings (TTM) | €12.34m |
| Revenue (TTM) | €28.83m |
2.4x
P/E Ratio1.0x
P/S RatioIs C4J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C4J income statement (TTM) | |
|---|---|
| Revenue | UK£24.68m |
| Cost of Revenue | UK£16.00k |
| Gross Profit | UK£24.66m |
| Other Expenses | UK£14.10m |
| Earnings | UK£10.57m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.042 |
| Gross Margin | 99.94% |
| Net Profit Margin | 42.81% |
| Debt/Equity Ratio | 0% |
How did C4J perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/29 17:45 |
| End of Day Share Price | 2024/04/26 00:00 |
| Earnings | 2024/01/31 |
| Annual Earnings | 2023/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
C4X Discovery Holdings plc is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julie Simmonds | Panmure Liberum Historic (Panmure Gordon) |
| Sean Conroy | Shore Capital Group Ltd |